Xu et al.29developed a nomogram to stratify older women with triple-negative breast cancer by RT risk, suggesting overall survival and breast cancer–specific survival benefits in high-risk patients, overall survival benefits only in intermediate-risk groups, and no observed benefits in low-risk patients (risk groups defined based on a numerical categorization of age, race, ERBB2 status, T stage, and N stage). This evidence concerns the gene ERBB2 and breast cancer.